Integra LifeSciences (NASDAQ:IART) Releases Earnings Results, Beats Estimates By $0.02 EPS

Integra LifeSciences (NASDAQ:IART) announced its quarterly earnings data on Monday. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02, Briefing.com reports. The business had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.76 earnings per share.

Integra LifeSciences Trading Up 1.5 %

IART stock traded up $0.37 during midday trading on Tuesday, hitting $24.49. 403,731 shares of the company’s stock were exchanged, compared to its average volume of 1,095,751. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The business has a 50-day simple moving average of $18.68 and a two-hundred day simple moving average of $24.41. The stock has a market capitalization of $1.90 billion, a PE ratio of 83.97, a P/E/G ratio of 0.66 and a beta of 1.08.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America lowered their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. JMP Securities lowered their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Morgan Stanley increased their price target on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. Finally, Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and an average target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.